Anebulo Pharmaceuticals Inc (ANEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 10,355 | 11,628 | 13,280 | 14,999 | 1,404 |
| Receivables | 10 | 73 | N/A | 31 | 245 |
| TOTAL | $10,535 | $11,963 | $13,808 | $15,396 | $1,963 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 166 | 183 | 201 | 446 | 505 |
| TOTAL | $166 | $183 | $201 | $446 | $505 |
| Total Assets | $10,701 | $12,146 | $14,009 | $15,841 | $2,468 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 608 | 224 | 428 | 320 | 252 |
| Accrued Expenses | 356 | 264 | 119 | 559 | 317 |
| TOTAL | $964 | $488 | $546 | $879 | $569 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $964 | $488 | $546 | $879 | $569 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 41,085 | 41,085 | 41,085 | 41,085 | 25,933 |
| Common Shares | 41 | 41 | 41 | 41 | 26 |
| Retained earnings | -76,047 | -73,889 | -71,744 | -70,068 | -67,605 |
| TOTAL | $9,737 | $11,658 | $13,463 | $14,962 | $1,899 |
| Total Liabilities And Equity | $10,701 | $12,146 | $14,009 | $15,841 | $2,468 |